Urology
MD, Attending Surgeon, Urologic Surgery, Sir Murray Brennan Endowed Chair in Surgery, Memorial Sloan Kettering Cancer Center Professor, Department of Urology, Weill Cornell Medical College, USA
Dr. Bochner is an attending surgeon on the Urology Service at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Urology at the Weill Medical College of Cornell University. He has served as a Vice Chairman of the Department of Surgery, co-Leader of the urothelial cancer disease management team and past co-Director of the Pelvic and Reconstructive Surgery group at MSKCC. Currently Dr. Bochner holds the Sir Murray Brennan Endowed Chair in Surgery at MSKCC. Dr Bochner’s clinical focus in on urologic oncology with a particular interest in urothelial cancer and pelvic reconstructive surgery. He is a co-PI as part of the MSKCC Bladder Cancer SPORE grant as well as the PI or coPI of several active phase 1-3 clinical trials. National participation includes numerous committees and task forces including the TCGA project for bladder cancer, the Genitourinary Task Force of the American Joint Committee on Cancer (AJCC) and AUA/SUO guideline committees. Dr Bochner is an elected member of the American Surgical Association; the current President elect of the Society of Pelvic Surgeons and a member of the American Association of Genitourinary Surgeons.
Selected publications from PubMed
Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.
Truong H, Eichholz J, White C, Ostrovnaya I, Chatila WK, Walch H, Sheikh R, Kemel Y, Liso N, Rosenberg J, Iyer G, Aggen DH, Funt SA, Basar M, Yol C, Lenis AT, Reisz P, Latham A, Stadler Z, Murciano-Goroff YR, Banaszak LG, Abbass M, Liu Y, Cha EK, Goh AC, Smith RC, Donahue TF, Matulewicz RS, Donat SM, Herr H, Reuter V, Mandelker D, Schultz N, Offit K, Bochner BH, Coleman JA, Pietzak E, Al-Ahmadie H, Solit DB, Carlo MI
J Natl Cancer Inst. 2026 Jul 16 pii: djag229. doi: 10.1093/jnci/djag229.
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
Katims AB, White C, Alam SM, Farha M, Sepehri S, De Jesus Escano M, D'Souza N, Gokturk Ozcan G, Basar M, Martinez Benitez A, McCarter M, Tomberlin M, Solit DB, Iyer G, Du P, Jia S, Goh AC, Donahue TF, Sarungbam J, Bochner BH, Kates M, Ostrovnaya I, Al-Ahmadie H, Lin O, Pietzak EJ
Clin Cancer Res. 2026 May 1;32(9):1755-1765 doi: 10.1158/1078-0432.CCR-25-3395.
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.
Guercio BJ, Pietzak EJ, Ravichandran V, Chen JF, Shah RH, Peters V, Regazzi AM, Niglio SA, Aggen DH, Funt SA, Donahue TF, Goh AC, Cha EK, Wong P, Richards AL, Cobbs CC, Donat SM, Dalbagni G, Bochner BH, Iyer G, Donoghue MTA, Ostrovnaya I, Al-Ahmadie HA, Rosenberg JE, Teo MY
Clin Cancer Res. 2026 Apr 15;32(8):1434-1444 doi: 10.1158/1078-0432.CCR-25-3771.
Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
Donahue TF, Assel M, Cha EK, Goh A, Pietzak E, Dalbagni G, Vickers A, Vargas HA, Fleming S, Bochner BH
J Urol. 2025 Nov;214(5):487-495 doi: 10.1097/JU.0000000000004703.
Patterns of Outpatient Urinalysis Testing and the Detection of Microscopic Hematuria.
Matulewicz RS, Gold SA, Baky F, Nicholson A, Wahlstedt E, Alba P, Bochner BH, Herr HW, Goldfarb DS, Lynch JA, Barlow LJ, Assel M, Vickers AJ, Sherman SE, Makarov DV
Urology. 2025 Nov;205:136-144 doi: 10.1016/j.urology.2025.07.004.
A clinical and scientific examination of Narrow Band Imaging (NBI) technology in bladder cancer management. Dr. Bochner details the biophysical mechanism of NBI, focusing on how the 415 nm and 540 nm wavelengths match hemoglobin absorption to highlight vascularization. The session reviews key clinical trial data on tumor detection sensitivity and showcases real cystoscopic comparisons of papillary and flat (CIS) lesions under white light versus NBI.
With Olympus
Published
Aug 2026
Join leading global experts for an exclusive scientific program dedicated to optimizing clinical outcomes in Non-Muscle-Invasive Bladder Cancer (NMIBC). This specialized session will delve into the latest guidelines, visual detection advancements like NBI and PDD, and future strategies to prevent recurrence. Don't miss this opportunity to gain valuable insights from international key opinion leaders, explore precision treatment pathways, and participate in an interactive panel discussion designed to elevate patient care standards.
With Olympus
Published
Jun 2026
Help your network discover Dr. Bernard H. Bochner's clinical expertise.
